` AMLX (Amylyx Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

AMLX
vs
S&P 500

Over the past 12 months, AMLX has significantly outperformed S&P 500, delivering a return of 187% compared to the S&P 500's 9% growth.

Stocks Performance
AMLX vs S&P 500

Loading
AMLX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
AMLX vs S&P 500

Performance Gap Between AMLX and GSPC
HIDDEN
Show

Performance By Year
AMLX vs S&P 500

Loading
AMLX
S&P 500
Add Stock

Competitors Performance
Amylyx Pharmaceuticals Inc vs Peers

S&P 500
AMLX
LLY
JNJ
NOVO B
ROG
Add Stock

Amylyx Pharmaceuticals Inc
Glance View

Market Cap
454.3m USD
Industry
Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2022-01-07. The firm is developing therapies for treatment paradigm for amyotrophic lateral sclerosis (ALS), and range of neurodegenerative diseases by keeping neurons alive. The firm is pursuing commercialization of its product candidate, AMX0035. AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO) also known as ursodoxicoltaurine. AMX0035 is designed to target the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. AMX0035 keep neurons alive under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of Alzheimer’s Disease (AD) and multiple sclerosis.

AMLX Intrinsic Value
Not Available
Back to Top